ROS1 and non-small cell lung carcinoma: However, acquired resistance inevitably develops, often through secondary mutations in the ROS1 kinase domain (e.g., ROS1 G2032R), activation of bypass signaling pathways such as EGFR or KIT, or epithelial-to-mesenchymal transition (10).Despite these challenges in NSCLC, the role of ROS1 rearrangements in MPM remains largely unexplored.